Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the shares. The firm notes Arrowhead entered a strategic partnership with ...

Arrowhead is also eligible for up to $10 billion in potential milestones and low double-digit royalties. Needham lowered Sarepta’s price target to $202 from $205, maintaining a ‘Buy’ rating.

A sure sign of winter in International Falls one week after the “Icebox Days” is still on target to be here, despite the record high temperatures earlier this month. Approximately 135 runners, ...

StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Citigroup dropped their target price on shares of Arrowhead Pharmaceuticals ...